“2024 is off to a great start with tremendous progress on our skeletal and cardiac muscle programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Most recently, we initiated our Phase 2 CIRRUS-HCM trial of EDG-7500 and announced positive 2-year topline data from our ARCH open label trial in Becker. We expect significant catalysts on our programs throughout this year including data from the CANYON and CIRRUS studies.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Names Arlene Morris New Class I Director
- Edgewise doses 1st patient in CIRRUS-HCM of EDG-7500 trial for HCM
- EMA grants Orphan Drug Designations for Edgewise’s sevasemten to treat Becker
- Edgewise Therapeutics price target raised to $32 from $28 at RBC Capital
- Edgewise reports ‘positive’ two-year topline results from ARCH trial